

Daily evidence digest

19 April 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

COVID-19 and kidney disease, fourth dose of Pfizer, protection following booster in adolescents, changes in life expectancy between 2019 & 2020

Peer reviewed journals featured:

- A narrative review on COVID-19 and kidney disease [here](#)
- Observational studies on:
 - Fourth dose of Comirnaty (Pfizer) vaccine in Israel [here](#)
 - Protection after Comirnaty (Pfizer) booster in adolescents [here](#)
 - Comirnaty (Pfizer) vaccine and booster in autoimmune rheumatic disease patients [here](#)
 - Population-level impact of a pulse oximetry remote monitoring program for COVID-19 on mortality and health service use in England [here](#)
 - Changes in life expectancy between 2019 & 2020 in the US and 21 peer countries [here](#)
- Modelling studies on:
 - The disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions [here](#)
 - The efficacy of indoor non-pharmaceutical interventions for COVID-19 outbreaks [here](#)
- Commentary on:
 - What is the evidence for the antiviral molnupiravir? [here](#)
 - Hong Kong's "dynamic zero" COVID-19 strategy, Omicron and vaccination rates [here](#)
 - Air filtration in public spaces [here](#)
 - NHS workforce shortages and staff burnout [here](#)

Pre-peer review articles featured:

- Comirnaty (Pfizer) vaccine fourth dose effectiveness in reducing SARS-CoV-2 infection among healthcare workers in Israel [here](#)
- Omicron neutralising antibody response to booster vaccination compared with breakthrough infection [here](#)
- Protection conferred by vaccine plus previous infection (hybrid immunity) with vaccines of three different platforms during Omicron wave in Brazil [here](#)
- Fomite route transmission risk of Omicron compared with the ancestral strain in households [here](#)

Guidance and reports

- The World Health Organization published:
 - Updates of its COVID-19 vaccine tracker [here](#) and COVID-19 epidemiological report [here](#)
 - A statement on the 11th meeting of the International Health Regulations (2005) Emergency Committee regarding the COVID-19 pandemic [here](#)

News and blogs

- COVID-19 vaccine intellectual property (IP) waiver agreed [here](#)
- COVID-19 hybrid immunity [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC or Long COVID\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).

The Daily Digest service is taking a break for the remainder of this week. The next edition will be released on Tuesday 26 April and will feature key publications released during the break.